Genprex, Inc. (GNPX) Stock Price, News, Quote & History - Yahoo Finance (2024)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},f=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(f(),setInterval((function(){f()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var m=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===m&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};

NasdaqCM - Delayed Quote • USD

Compare

1.9700 +0.0700 (+3.68%)

At close: July 2 at 4:00 PM EDT

1.9900 +0.02 (+1.02%)

After hours: July 2 at 4:25 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for GNPX

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

• Previous Close 1.9000
• Open 1.9600
• Bid --
• Ask --
• Day's Range 1.8900 - 1.9999
• 52 Week Range 1.8700 - 42.0000
• Volume 20,662
• Avg. Volume 104,745
• Market Cap (intraday) 4.134M
• Beta (5Y Monthly) -0.53
• PE Ratio (TTM) --
• EPS (TTM) -18.8100
• Earnings Date Aug 21, 2024 - Aug 26, 2024
• Forward Dividend & Yield --
• Ex-Dividend Date --
• 1y Target Est 165.00

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

www.genprex.com

26

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Genprex, Inc.

Recent News: GNPX

View More

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Tender Offer/Acquisition Reports

Offering Registrations

See Also

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis2024-06-27 | Genprex Issues Stockholder Letter and Provides 2024 Corporate Update | NDAQ:GNPX | Press ReleaseGenprex Inc (GNPX) Stock Message Board | InvestorsHubGenprex Inc (GNPX) Stock Price & News - Google Finance

View More

Performance Overview: GNPX

Trailing total returns as of 7/2/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GNPX

78.59%

S&P 500

15.50%

1-Year Return

GNPX

94.81%

S&P 500

23.79%

3-Year Return

GNPX

98.53%

S&P 500

27.53%

5-Year Return

GNPX

95.83%

S&P 500

85.84%

Compare To: GNPX

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

GNPXGenprex, Inc.

1.9700

+3.68%

Mkt Cap 4.134M

Industry Biotechnology

CRDFCardiff Oncology, Inc.

2.0800

+1.46%

Mkt Cap 93.053M

Industry Biotechnology

IPAImmunoPrecise Antibodies Ltd.

1.0400

+4.54%

Mkt Cap 27.368M

Industry Biotechnology

CNSPCNS Pharmaceuticals, Inc.

1.2600

-11.27%

Mkt Cap 1.065M

Industry Biotechnology

CELZCreative Medical Technology Holdings, Inc.

3.6900

-1.47%

Mkt Cap 4.975M

Industry Biotechnology

ATNMActinium Pharmaceuticals, Inc.

6.96

-3.33%

See Also

GNPX Stock | Message Board | Genprex Inc. - Investors Hangout

Mkt Cap 207.293M

Industry Biotechnology

BRTXBioRestorative Therapies, Inc.

1.9200

-3.03%

Mkt Cap 12.998M

Industry Biotechnology

IMMXImmix Biopharma, Inc.

1.9600

-7.55%

Mkt Cap 51.772M

Industry Biotechnology

COCPCocrystal Pharma, Inc.

2.3600

-1.26%

Mkt Cap 24.01M

Industry Biotechnology

ELDNEledon Pharmaceuticals, Inc.

2.4100

-3.98%

Mkt Cap 92.801M

Industry Biotechnology

VRAXVirax Biolabs Group Limited

1.1000

0.00%

Mkt Cap 2.598M

Industry Biotechnology

Statistics: GNPX

View More

Valuation Measures

Annual

As of 7/2/2024

• Market Cap

  4.13M

• Enterprise Value

  -4.08M

• Trailing P/E

  --

• Forward P/E

  --

• PEG Ratio (5yr expected)

  --

• Price/Sales (ttm)

  --

• Price/Book (mrq)

  0.47

• Enterprise Value/Revenue

  --

• Enterprise Value/EBITDA

  0.18

Financial Highlights

Profitability and Income Statement

• Profit Margin

  0.00%

• Return on Assets (ttm)

  -96.86%

• Return on Equity (ttm)

  -202.83%

• Revenue (ttm)

  --

• Net Income Avi to Common (ttm)

  -27.63M

• Diluted EPS (ttm)

  -18.8100

Balance Sheet and Cash Flow

• Total Cash (mrq)

  8.22M

• Total Debt/Equity (mrq)

  --

• Levered Free Cash Flow (ttm)

  -13.02M

View More

Research Analysis: GNPX

View More

View More

Company Insights: GNPX

Research Reports: GNPX

View More

View More

People Also Watch

DARE Daré Bioscience, Inc.

3.6300

-4.22%

CODX Co-Diagnostics, Inc.

1.2300

-2.38%

COCP Cocrystal Pharma, Inc.

2.3600

-1.26%

AIM AIM ImmunoTech Inc.

0.3604

-3.56%

AYTU Aytu BioPharma, Inc.

2.8600

-1.38%

OPGN OpGen, Inc.

2.6200

+4.38%

VTVT vTv Therapeutics Inc.

18.28

+3.04%

AGRX Agile Therapeutics, Inc.

1.4100

-0.70%

NNVC NanoViricides, Inc.

1.7800

-3.78%

CTXR Citius Pharmaceuticals, Inc.

0.5121

-5.74%

PIXY ShiftPixy, Inc.

1.7200

+1.18%

CAPR Capricor Therapeutics, Inc.

4.7200

-2.48%

CLSD Clearside Biomedical, Inc.

1.2300

-0.81%

HOTH Hoth Therapeutics, Inc.

0.8830

-6.06%

BSGM BioSig Technologies, Inc.

0.3501

+0.03%

VBIV VBI Vaccines Inc.

0.7110

+2.75%